Publication

Systemic vasculitis developed after immune checkpoint inhibition: Comment on the article by Cappelli et al

Rutgers, A., van den Brom, R. R. H., Hospers, G. A. P., Heeringa, P. & Brouwer, E., Aug-2018, In : Arthritis Care and Research. 70, 8, p. 1275 1 p.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Copy link to clipboard

Documents

  • Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli et al

    Final publisher's version, 81 KB, PDF-document

DOI

With much interest, we read the recent systematic review on rheumatic and musculoskeletal immune-related adverse events (IRAEs) due to immune checkpoint inhibitors by Cappelli et al1 . The mechanistic basis on which the immune checkpoint inhibitors cause immune-related adverse events, dictates that basically any autoimmune disease could occur at an increased frequency in any of the patients treated with these agents. We think there is an underestimation of autoimmune disease development in these patients due to patient underreporting and physician unfamiliarity.

Original languageEnglish
Pages (from-to)1275
Number of pages1
JournalArthritis Care and Research
Volume70
Issue number8
Publication statusPublished - Aug-2018

    Keywords

  • Journal Article

View graph of relations

ID: 51259205